問卷

TPIDB > Principal Investigator

Principal Investigator


National Taiwan University Hospital Hsin-Chu Branch (在職)

Division of Nephrology

更新時間:2023-09-19

楊忠煒
  • Principal Investigator
  • Clinical Trial Experience (year)

篩選

List

8Cases

2021-08-31 - 2026-12-31

Phase III

Completed
  • Condition/Disease

  • Test Drug

Participate Sites
18Sites

Not yet recruiting9Sites

Recruiting9Sites

2023-12-01 - 2029-06-30

Phase III

Active
A Phase 3, Randomized, Double-blind, Placebo-controlled Study of BION-1301 in Adults with IgA Nephropathy (The BEYOND Study)
  • Condition/Disease

    Adults with IgA Nephropathy

  • Test Drug

    injection

Participate Sites
8Sites

Recruiting8Sites

2023-12-01 - 2029-06-30

Phase III

Active
A Phase 3, Randomized, Double-blind, Placebo-controlled Study of BION-1301 in Adults With IgA Nephropathy (The BEYOND Study)
  • Condition/Disease

    IgA Nephropathy 、Immunoglobulin A Nephropathy

  • Test Drug

    皮下注射劑

Participate Sites
8Sites

Recruiting8Sites

2021-03-01 - 2026-12-31

Phase III

Active
  • Condition/Disease

  • Test Drug

Participate Sites
5Sites

Recruiting5Sites

2021-03-01 - 2026-12-31

Phase III

Active
  • Condition/Disease

  • Test Drug

Participate Sites
5Sites

Recruiting5Sites

2021-09-21 - 2026-06-01

Phase III

Active
  • Condition/Disease

  • Test Drug

Participate Sites
9Sites

Recruiting9Sites

2023-12-01 - 2029-06-30

Phase III

A Phase 3, Randomized, Double-blind, Placebo-controlled Study of BION-1301 in Adults with IgA Nephropathy (The BEYOND Study)
  • Condition/Disease

    IgA Nephropathy

  • Test Drug

    BION-1301

Participate Sites
8Sites

Not yet recruiting8Sites

2021-03-01 - 2025-11-30

Phase III

A Phase 3, Randomized, Double-Blind, Placebo-Controlled Study of Atrasentan in Patients with IgA Nephropathy at Risk of Progressive Loss of Renal Function (The ALIGN Study)
  • Condition/Disease

    IgA Nephropathy at Risk of Progressive Loss of Renal Function

  • Test Drug

    Atrasentan

Participate Sites
5Sites

Not yet recruiting3Sites

Recruiting2Sites